稳定型心绞痛患者血尿酸水平与冠状动脉钙化程度的相关性

doi:10.3969/j.issn.1004-583X.2025.03.003

摘要/Abstract

摘要：

目的探讨稳定型心绞痛(stable angina pectoris,SAP)患者血尿酸(serum uric acid, SUA)水平与冠状动脉钙化(coronary artery calcification, CAC)程度的相关性,为CAC的诊断和评估提供依据。方法选择2021年9月—2024年8月在北京市仁和医院诊断为SAP的患者125例,并于北京市仁和医院行冠状动脉CTA扫描,采用Agatston修正法计算冠状动脉钙化积分(coronary artery calcification score, CACS)后将患者分为5组:无钙化组(CACS=0,n=11)、少量钙化组(1≤CACS≤10,n=34)、轻度钙化组(11≤CACS≤100,n=26)、中度钙化组(101≤CACS≤399,n=36 )、重度钙化组(CACS≥400,n=18)。比较各组临床资料,采用logistic回归分析筛选CAC的影响因素,采用相关性分析探讨SUA水平与其他指标的相关性,采用受试者工作特征曲线分析评估SUA水平预测CAC严重程度的价值。结果 5组性别、年龄、饮酒史、甘油三酯(triglycerides, TG)、低密度脂蛋白胆固醇(low-density lipoprotein cholesterol, LDL-C)、脂蛋白α[lipoprotein(α), Lp(α)]水平差异均无统计学意义(P>0.05);高血压病史占比、糖尿病史占比、吸烟史占比、总胆固醇(total cholesterol, TC)水平、SUA水平差异均有统计学意义(P<0.05)。行有序logistic回归分析,结果表明,高血压病史、糖尿病史、吸烟史、饮酒史、TG、TC、LDL-C、LP(α)、SUA均为CAC的危险因素(P<0.05)。相关性分析表明,SUA水平与TC、LDL-C、LP(α)和CAC程度均呈正相关(P<0.05)。绘制受试者工作特征曲线显示,SUA水平预测CAC的曲线下面积为0.884(95%CI: 0.816~0.951),截断值为367.5 μmol/L,敏感度为81.6%,特异度为90.9%。结论 SAP患者SUA水平与CAC程度呈正相关,可作为独立危险因素,且对CAC有一定的预测价值。

关键词: 心绞痛, 稳定型, 血管钙化, 冠状血管, 血尿酸, 相关性分析

Abstract:

Objective To investigate the correlation between serum uric acid (SUA) levels and coronary artery calcification (CAC) severity in patients with stable angina pectoris (SAP), thus providing a basis for the diagnosis and assessment of CAC. Methods A total of 125 patients diagnosed with SAP in Beijing Renhe Hospital from September 2021 to August 2024 were recruited, and all patients were given CTA scan in the hospital. After calculating the Agatston coronary artery calcification score (CACS), the patients were divided into non-calcification group (CACS=0, n=11), less calcification group (1≤CACS≤10, n=34), mild calcification group (11≤CACS≤100, n=26), moderate calcification group (101≤CACS≤399, n=36), severe calcification group (CACS≥400, n=18). The clinical data of each group were compared. Logistic regression analysis was employed to screen the influencing factors of CAC. Correlation analysis was used to explore the correlation between SUA level and other indicators. Receiver operating characteristic (ROC) curve analysis was applied to evaluate the value of SUA level in predicting CAC severity. Results There were no significant differences in gender, age, drinking history, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and lipoprotein (α) (Lp[α]) levels among the five groups (P>0.05). There were statistically significant differences in the proportions of hypertension, diabetes and smoking, and levels of total cholesterol (TC) and SUA (P<0.05). The results of ordinal logistic regression analysis showed that hypertension history, diabetes history, smoking history, drinking history, TG, TC, LDL-C, LP (α) and SUA were all risk factors for CAC (P<0.05). Correlation analysis showed that SUA level was positively correlated with TC, LDL-C, LP (α) and CAC severity (P<0.05). The area under ROC curve (AUC) of SUA level in predicting CAC severity was 0.884(95%CI: 0.816-0.951), with the cutoff value of 367.5 μmol/L, the sensitivity of 81.6%, and the specificity of 90.9%. Conclusion SUA levels in SAP patients are positively correlated with CAC severity, making SUA an independent risk factor with certain diagnostic value for CAC.

Key words: angina, stable, vascular calcification, coronary vessels, serum uric acid, correlation analysis

中图分类号:

R541.4

刘胜华. 稳定型心绞痛患者血尿酸水平与冠状动脉钙化程度的相关性[J]. 临床荟萃, 2025, 40(3): 211-216.

Liu Shenghua. Correlation between serum uric acid levels and coronary artery calcification severity in patients with stable angina pectoris[J]. Clinical Focus, 2025, 40(3): 211-216.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2025.03.003

https://lchc.magtechjournal.com/CN/Y2025/V40/I3/211

图/表 5

参考文献 29

[1]	王斌, 冯建飞, 刘信信. 脑心通胶囊对慢性稳定型心绞痛合并高血压患者的治疗效果[J]. 内蒙古中医药, 2024, 43(9): 25-26.
[2]	薛子璇, 柏宝辰, 侯昌, 等. 冠状动脉钙化形成机制与新型评估法的研究进展[J]. 中国心血管病研究, 2021, 19(11): 1044-1049.
[3]	Tanimura A, McGregor DH, Anderson HC. Matrix vesicles in atherosclerotic calcification[J]. Proc Soc Exp Biol Med, 1983, 172(2): 173-177. doi: 10.3181/00379727-172-41542 pmid: 6828462
[4]	中国心血管健康与疾病报告2023概要[J]. 中国循环杂志, 2024, 39(7):625-660.
[5]	曹紫晨, 金梦龙, 付真彦. 高尿酸血症与心脑血管疾病的研究进展[J]. 医学研究杂志, 2024, 53(2): 164-168.
[6]	Kim H, Kim SH, Choi A, et al. Asymptomatic hyperuricemia is independently associated with coronary artery calcification in the absence of overt coronary artery disease: A single-center cross-sectional study[J]. Medicine (Baltimore), 2017, 96(14): e6565.
[7]	Liang L, Hou X, Bainey KR, et al. The association between hyperuricemia and coronary artery calcification development: A systematic review and meta-analysis[J]. Clin Cardiol, 2019, 42(11): 1079-1086. doi: 10.1002/clc.23266 pmid: 31571239
[8]	高静媛, 韩黎明, 梁芳倩, 等. 人血尿酸与中老年人冠状动脉钙化程度的相关性分析[J]. 中国现代医生, 2022, 60(24): 27-31.
[9]	中华医学会心血管病学分会介入心脏病学组, 中华医学会心血管病学分会动脉粥样硬化与冠心病学组, 中国医师协会心血管内科医师分会血栓防治专业委员会, 等. 稳定性冠心病诊断与治疗指南[J]. 中华心血管病杂志, 2018, 46(9):680-694.
[10]	杨义文, 胡春洪. 冠状动脉钙化积分的临床研究[J]. 中国临床医生杂志, 2023, 51(11):1269-1271.
[11]	McClelland RL, Chung H, Detrano R, et al. Distribution of coronary artery calcium by race, gender, and age: Results from the Multi-Ethnic Study of Atherosclerosis (MESA)[J]. Circulation, 2006, 113(1): 30-37. doi: 10.1161/CIRCULATIONAHA.105.580696 pmid: 16365194
[12]	Patil HR, O'Keefe JH, Lavie CJ, et al. Cardiovascular damage resulting from chronic excessive endurance exercise[J]. Mo Med, 2012, 109(4): 312-321. pmid: 22953596
[13]	赵璐, 袁宇. 冠心病患者Hcy、Fg、hsCRP、D-D水平与肠道菌群相关性的分析[J]. 心血管康复医学杂志, 2022, 31(1):28-32.
[14]	McEvoy JW, Nasir K, DeFilippis AP, et al. Relationship of cigarette smoking with inflammation and subclinical vascular disease: The multi-ethnic study of atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2015, 35(4): 1002-1010. doi: 10.1161/ATVBAHA.114.304960 pmid: 25745060
[15]	Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: An update[J]. J Am Coll Cardiol, 2004, 43(10): 1731-1737. doi: 10.1016/j.jacc.2003.12.047 pmid: 15145091
[16]	Won KB, Han D, Lee JH, et al. Atherogenic index of plasma and coronary artery calcification progression beyond traditional risk factors according to baseline coronary artery calcium score[J]. Sci Rep, 2020, 10(1): 21324.
[17]	中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1):24-56.
[18]	刘高华, 潘曙峰, 孙文英. 糖尿病合并不稳定型心绞痛患者血清总胆固醇低密度脂蛋白胆固醇水平与冠脉病变程度的相关性[J]. 基层医学论坛, 2021, 25(34):4885-4887.
[19]	蔺想军. WMR、LDL-C/HDL-C与冠脉病变严重程度的预测价值研究[D]. 川北医学院, 2023.
[20]	徐洪繁. 他汀、脂蛋白(a)对冠状动脉钙化影响的横断面研究[D]. 大理大学, 2021.
[21]	韩黎明, 高静媛, 严涵, 等. 红细胞计数、血尿酸与中老年人冠状动脉钙化严重程度关系研究及预测模型建立[J]. 中国循证心血管医学杂志, 2023, 15(10):1203-1207+1211.
[22]	Kiss LZ, Bagyura Z, Csobay-Novák C, et al. Serum uric acid is independently associated with coronary calcification in an asymptomatic population[J]. J Cardiovasc Transl Res, 2019, 12(3): 204-210. doi: 10.1007/s12265-018-9843-8 pmid: 30414068
[23]	徐彧, 杜丰夷, 袁小佳, 等. 慢性冠脉综合征患者血尿酸及钙化积分对CT-FFR的影响[J]. 中国中西医结合影像学杂志, 2024, 22(2):175-179.
[24]	陈尔意. 四妙丸治疗急性冠脉综合征炎症合并高尿酸血症的临床研究[D]. 上海中医药大学, 2020.
[25]	倪海燕. 血尿酸激活NLRP3炎性体参与冠脉局部炎症反应的研究[D]. 川北医学院, 2014.
[26]	吴小雯, 朱晓琳, 杨亚丽, 等. 无症状高尿酸血症对血管内皮功能的损害机制的研究进展[J]. 中国医药导报, 2023, 20(36):46-49.
[27]	安然, 韩建妙, 张倩, 等. 血尿酸、肠道菌群、miR-25水平与老年慢性心力衰竭患者心功能的相关性及对诊断的价值[J]. 疑难病杂志, 2024, 23(10):1198-1202.
[28]	Son M, Seo J, Yang S. Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017[J]. PLoS One, 2020, 15(2): e0228684.
[29]	Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines[J]. J Hypertens, 2020, 38(6): 982-1004.

组别		例数	男性[例(%)]		年龄(岁)		高血压病史[例(%)]		糖尿病史[例(%)]			吸烟史[例(%)]
无钙化组		11	6(54.6)		63.09±9.56		3(27.3)		4(36.4)			1(9.1)
少量钙化组		34	18(52.9)		61.85±10.90		9(26.5)		10(29.4)			7(20.6)
轻度钙化组		26	13(50.0)		58.81±8.80		9(34.6)		11(42.3)			10(38.5)
中度钙化组		36	18(50.0)		64.67±9.80		17(47.2)		20(55.6)^*#			14(38.9)
重度钙化组		18	11(61.1)		63.11±11.31		15(83.3)^*#△▲		13(72.2)^*#			13(72.2)^*#△▲
F/χ²值			0.58		1.32		17.90		10.61			17.41
P值			0.97		0.26		<0.01		0.03			<0.01
组别	饮酒史[例(%)]			TG(mmol/L)		TC(mmol/L)		LDL-C(mmol/L)		LP(α)(mg/dL)	SUA(μmol/L)
无钙化组	2(18.2)			1.13±0.31		3.73±0.91		3.04±0.86		12.01±4.20	343.5.20±28.23
少量钙化组	8(23.5)			1.32±0.42		4.65±1.00		3.14±0.82		12.02±2.28	385.30±41.41
轻度钙化组	11(42.3)			1.35±0.27		5.16±1.26^*		3.29±0.93		12.80±3.45	402.20±59.49^*
中度钙化组	14(38.9)			1.43±0.36		5.47±0.77^*#		3.62±1.05		13.57±2.69	455.20±50.75^*#
重度钙化组	11(61.1)			1.45±0.19		6.24±0.87^*#△		3.65±0.93		14.83±3.37	499.30±32.23^*#△▲
F/χ²值	9.20			2.51		14.51		0.91		2.41	36.16
P值	0.06			0.05		<0.01		0.11		0.05	<0.01

组别		例数	男性[例(%)]		年龄(岁)		高血压病史[例(%)]		糖尿病史[例(%)]			吸烟史[例(%)]
无钙化组		11	6(54.6)		63.09±9.56		3(27.3)		4(36.4)			1(9.1)
少量钙化组		34	18(52.9)		61.85±10.90		9(26.5)		10(29.4)			7(20.6)
轻度钙化组		26	13(50.0)		58.81±8.80		9(34.6)		11(42.3)			10(38.5)
中度钙化组		36	18(50.0)		64.67±9.80		17(47.2)		20(55.6)^*#			14(38.9)
重度钙化组		18	11(61.1)		63.11±11.31		15(83.3)^*#△▲		13(72.2)^*#			13(72.2)^*#△▲
F/χ²值			0.58		1.32		17.90		10.61			17.41
P值			0.97		0.26		<0.01		0.03			<0.01
组别	饮酒史[例(%)]			TG(mmol/L)		TC(mmol/L)		LDL-C(mmol/L)		LP(α)(mg/dL)	SUA(μmol/L)
无钙化组	2(18.2)			1.13±0.31		3.73±0.91		3.04±0.86		12.01±4.20	343.5.20±28.23
少量钙化组	8(23.5)			1.32±0.42		4.65±1.00		3.14±0.82		12.02±2.28	385.30±41.41
轻度钙化组	11(42.3)			1.35±0.27		5.16±1.26^*		3.29±0.93		12.80±3.45	402.20±59.49^*
中度钙化组	14(38.9)			1.43±0.36		5.47±0.77^*#		3.62±1.05		13.57±2.69	455.20±50.75^*#
重度钙化组	11(61.1)			1.45±0.19		6.24±0.87^*#△		3.65±0.93		14.83±3.37	499.30±32.23^*#△▲
F/χ²值	9.20			2.51		14.51		0.91		2.41	36.16
P值	0.06			0.05		<0.01		0.11		0.05	<0.01

变量	赋值
因变量
CAC	无钙化=1,少量钙化=2,轻度钙化=3,中度钙化=4,重度钙化=5
自变量
既往史
高血压病史	有=1,无=0
糖尿病史	有=1,无=0
个人史
吸烟史	有=1,无=0
饮酒史	有=1,无=0
TG	连续变量
TC	连续变量
LDL-C	连续变量
LP(α)	连续变量
SUA	连续变量

变量	赋值
因变量
CAC	无钙化=1,少量钙化=2,轻度钙化=3,中度钙化=4,重度钙化=5
自变量
既往史
高血压病史	有=1,无=0
糖尿病史	有=1,无=0
个人史
吸烟史	有=1,无=0
饮酒史	有=1,无=0
TG	连续变量
TC	连续变量
LDL-C	连续变量
LP(α)	连续变量
SUA	连续变量

因素	回归系数	标准误	Wald χ²值	P值	OR值	95%可信区间
高血压病史	1.309	0.342	14.622	<0.05	3.702	0.638~1.979
糖尿病史	1.027	0.332	9.591	<0.05	2.793	0.377~1.677
吸烟史	1.347	0.353	14.574	<0.05	3.846	0.656~2.039
饮酒史	0.931	0.340	7.480	<0.05	2.537	0.264~1.598
TG	1.125	0.472	5.697	<0.05	3.080	0.201~2.050
TC	1.204	0.164	54.199	<0.05	3.333	0.844~1.525
LDL-C	0.448	0.174	6.614	<0.05	1.565	0.107~0.789
LP(α)	0.168	0.055	9.388	<0.05	1.183	0.061~0.276
SUA	0.027	0.003	59.216	<0.05	1.027	0.020~0.033